CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,293,720 | +1112.7% | 312,499 | +634.8% | 0.00% | – |
| Q2 2023 | $766,355 | +50218.8% | 42,528 | -55.1% | 0.00% | -100.0% |
| Q1 2023 | $1,523 | -85.5% | 94,807 | -83.5% | 0.00% | -83.3% |
| Q4 2022 | $10,531 | -99.8% | 575,488 | +78.9% | 0.01% | +50.0% |
| Q3 2022 | $6,319,000 | -33.5% | 321,752 | -36.8% | 0.00% | -33.3% |
| Q2 2022 | $9,499,000 | +83.2% | 509,330 | +115.7% | 0.01% | +100.0% |
| Q1 2022 | $5,184,000 | +453.8% | 236,160 | +616.5% | 0.00% | – |
| Q4 2021 | $936,000 | +267.1% | 32,959 | +172.1% | 0.00% | – |
| Q3 2021 | $255,000 | +24.4% | 12,112 | -16.7% | 0.00% | – |
| Q4 2020 | $205,000 | -89.6% | 14,538 | -87.1% | 0.00% | -100.0% |
| Q2 2020 | $1,980,000 | +337.1% | 113,034 | +526.5% | 0.00% | +200.0% |
| Q4 2019 | $453,000 | -45.4% | 18,041 | -67.3% | 0.00% | 0.0% |
| Q3 2019 | $829,000 | +310.4% | 55,149 | +520.5% | 0.00% | – |
| Q1 2019 | $202,000 | – | 8,888 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |